Saturday, December 6, 2025

Latest

CloudMD Announces $10M Bought Deal

This evening CloudMD Software & Services Inc. (CSE: DOC) announced a $10M bought deal with a syndicate of underwriters co-led by Canaccord and Beacon. The underwriters agreed to purchase 14.3M units at a price of C$0.70 per unit with a full warrant priced at $1.00.

The stock has been on a role for the last month reaching a 52 week high of 95c.

The company also states they intend to use the proceeds of the offering for potential M&A activities to support their strategic growth plans and general corporate purposes.

The units will be offered by way of a short form prospectus and expected to close on June 2nd. The company granted the underwriters an option to purchase up to an additional 2.1M units at a price of C$0.70 per unit, exercisable at any time, for a period of 30 days after and including the closing date, which would result in additional proceeds of approximately C$1.5 million.

For full details, read the official company press release here.

The stock was halted all day and last traded at 77c.


FULL DISCLOSURE: CloudMD Software & Services is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover CloudMD Software & Services on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Why Copper Is Heading To $30 And Silver To $200 | Craig Parry

Mako Mining Q3 Earnings: The Transitional Quarter

B2Gold Q3 Earnings: Goose Troubles Cloud The Narrative

Recommended

Emerita Resources Awards Contract For Pre-Feasibility Study On Iberian Belt West Project

Selkirk Copper Appoints Two Members Of Selkirk First Nation To Leadership Team

Related News

Coronavirus Cases Continue to Soar Across the US, Surge in Death Rates Follows Suit

As the coronavirus pandemic continues to spread around the world, there is one country in...

Saturday, August 1, 2020, 05:06:00 PM

CloudMD: Canaccord Drops Price Target To $3.00 Following MindBeacon Deal

On November 15th, CloudMD Software & Services (TSXV: DOC) announced that they would be acquiring...

Friday, November 19, 2021, 04:14:00 PM

Three Things to Know About ‘Phase 3 COVID Player’: Revive Therapeutics

Bucillamine Just Got Cleared for Phase 3 Trials of COVID-19 On Friday, July 31, 2020...

Monday, August 3, 2020, 10:11:55 AM

Meat Processing Plants Turning to Robot Butchers to Reduce Coronavirus Infection Rates Among Workers

As the coronavirus pandemic continues to sweep across the US with record breaking infection rates,...

Sunday, July 12, 2020, 03:01:00 PM

Gilead’s Antiviral Drug Fails to Treat Coronavirus, Preliminary Study Shows

Gilead Sciences Inc (NASDAQ: GILD) has been running a randomized clinical trial on the experimental...

Thursday, April 23, 2020, 04:16:38 PM